Hypera (HYPE3) Corporate presentation summary

Mission and strategic vision

• Aims to provide access to health for Brazilians with high-quality, safe products and sustainable growth through innovation and social responsibility.

• Focuses on continuous investment in R&D and expanding its branded portfolio across all pharmaceutical segments.

Market position and growth

• Holds a leading position in Brazil’s pharmaceutical retail market, with a diversified presence in OTC, generics, skincare, and prescription drugs.

• Achieved a CAGR of 14% in sell-out revenue from 2018 to 2025, reaching R$11.5bn, and expanded to five business units.

• Top 10 brands accounted for 38% of retail sales in 2025, with over 80% of sales from branded products.

Portfolio and innovation

• Maintains a unique, irreplicable portfolio with leading brands in pain, flu, skincare, gastroenterology, and vitamins.

• Invested R$513.6mn in R&D in 2025, with a robust pipeline of 175 prescription and 152 OTC launches planned.

• Strategic partnerships and the Hynova innovation center support over 1,000 simultaneous projects and 100% ANVISA approval since 2017.